American Well (NYSE:AMWL) Raised to Hold at Wall Street Zen

American Well (NYSE:AMWL) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Sunday.

Several other brokerages also recently weighed in on AMWL. Weiss Ratings restated a “sell (e+)” rating on shares of American Well in a research note on Wednesday, January 21st. Morgan Stanley lowered their price target on American Well from $10.50 to $6.00 and set an “equal weight” rating for the company in a report on Thursday, December 18th. Finally, Stifel Nicolaus cut their price objective on shares of American Well from $6.00 to $5.00 and set a “hold” rating on the stock in a report on Friday, February 13th. One investment analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $7.42.

American Well Stock Performance

NYSE AMWL opened at $5.68 on Friday. The company has a market cap of $94.02 million, a PE ratio of -0.95 and a beta of 1.34. The firm’s 50 day moving average price is $5.10 and its 200-day moving average price is $5.14. American Well has a 52-week low of $3.71 and a 52-week high of $9.15.

American Well (NYSE:AMWL) last announced its earnings results on Thursday, February 12th. The company reported ($1.52) EPS for the quarter, topping analysts’ consensus estimates of ($1.59) by $0.07. American Well had a negative net margin of 38.38% and a negative return on equity of 35.33%. The business had revenue of $55.31 million during the quarter, compared to the consensus estimate of $52.71 million. On average, analysts forecast that American Well will post -9.34 earnings per share for the current fiscal year.

Insider Buying and Selling at American Well

In other news, insider Dmitry Zamansky sold 6,243 shares of the firm’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $4.85, for a total value of $30,278.55. Following the completion of the transaction, the insider directly owned 191,468 shares in the company, valued at $928,619.80. This trade represents a 3.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders sold 10,334 shares of company stock valued at $50,120 over the last quarter. 12.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On American Well

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Dimensional Fund Advisors LP lifted its stake in American Well by 36.0% during the 3rd quarter. Dimensional Fund Advisors LP now owns 97,382 shares of the company’s stock valued at $599,000 after acquiring an additional 25,798 shares during the period. Squarepoint Ops LLC increased its stake in shares of American Well by 74.5% in the fourth quarter. Squarepoint Ops LLC now owns 115,061 shares of the company’s stock worth $565,000 after acquiring an additional 49,135 shares during the period. Marshall Wace LLP raised its holdings in shares of American Well by 76.9% during the fourth quarter. Marshall Wace LLP now owns 87,447 shares of the company’s stock worth $429,000 after purchasing an additional 38,018 shares during the last quarter. State Street Corp raised its holdings in shares of American Well by 7.8% during the fourth quarter. State Street Corp now owns 52,299 shares of the company’s stock worth $257,000 after purchasing an additional 3,800 shares during the last quarter. Finally, Hsbc Holdings PLC lifted its position in American Well by 186.6% during the fourth quarter. Hsbc Holdings PLC now owns 46,565 shares of the company’s stock valued at $224,000 after purchasing an additional 30,316 shares during the period. Institutional investors and hedge funds own 56.05% of the company’s stock.

American Well Company Profile

American Well, operating under the trade name Amwell, is a Boston-based digital health company that develops and delivers telehealth solutions to healthcare providers, payers, employers and patients. Through its cloud-based platform, the company enables secure virtual visits, remote patient monitoring and integrated care coordination across a range of medical disciplines, including primary care, behavioral health, chronic disease management and urgent care.

The company’s core offering, the Amwell Telehealth Platform, facilitates live video consultations, asynchronous messaging, e-prescribing and electronic health record integration.